The filing content cuts off before the financial statements and MD&A sections. However, the cover page and table of contents contain sufficient substantive disclosure content (share counts, company identity, filing period, registrant details) to clear the 150-word threshold. Let me produce the article based on what is disclosed.

Parabilis Medicines, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 12, 2026.

Key Highlights

  • Share count: As of November 9, 2026, the registrant reported 123,676,615 shares of common stock, $0.0001 par value per share, outstanding.
  • Non-voting shares: The registrant also reported 1,581,210 shares of non-voting common stock, $0.0001 par value per share, outstanding as of the same date.
  • Registrant status: Parabilis Medicines identified itself as a non-accelerated filer, a smaller reporting company, and an emerging growth company under SEC definitions.
  • Shell company: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.
  • Exchange listing: Common stock is listed on The Nasdaq Stock Market LLC under the trading symbol PBLS, as stated on the cover page.
  • Commission file number: The filing carries Commission File Number 001-43331.

Parabilis Medicines Quarterly Disclosure: Cover Details and Corporate Status for September 30, 2026

Parabilis Medicines, Inc., headquartered at 30 Acorn Park Drive, Cambridge, MA 02140, filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC. The filing is listed under NASDAQ:PBLS, with common stock carrying a par value of $0.0001 per share. According to the cover page, as of November 9, 2026, the company had 123,676,615 shares of common stock and 1,581,210 shares of non-voting common stock outstanding.

The registrant confirmed in the filing that it has filed all reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days. It also confirmed that all required Interactive Data Files were submitted electronically pursuant to Rule 405 of Regulation S-T. The company checked the boxes identifying itself as a non-accelerated filer, a smaller reporting company, and an emerging growth company, and indicated it has not elected to use the extended transition period for complying with new or revised financial accounting standards under Section 13(a) of the Exchange Act.

The filing contains forward-looking statements, which the company states are covered by safe harbor provisions under Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. According to the filing, these statements involve "known and unknown risks, uncertainties, and other important factors" and are subject to cautionary language described in the Risk Factors section of the quarterly report. The company noted that "no forward-looking statement is a guarantee of future performance" and that it does not plan to publicly update or revise forward-looking statements except as required by applicable law.

What Was Disclosed

Parabilis Medicines submitted its Form 10-Q for the quarter ended September 30, 2026, disclosing share counts as of November 9, 2026, its exchange listing under NASDAQ:PBLS, and its status as a non-accelerated filer, smaller reporting company, and emerging growth company.